ALEXANDRIA BONNER: Open Payments
NPI 1427575489 · AMES, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$794 in 43 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $794
Food & beverage: $794
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $195 |
| Vanda Pharmaceuticals Inc. | 3 | $80 |
| Neurocrine BioSciences, Inc. | 3 | $80 |
| Alkermes, Inc. | 3 | $67 |
| Janssen Pharmaceuticals, Inc | 3 | $55 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| MDD US Operations, LLC | 2 | $33 |
Products named: VRAYLAR, FANAPT, INGREZZA, ARISTADA, CAPLYTA, REXULTI, UZEDY, Auvelity.
Industry payments across IA — which companies pay providers there.
